Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus DELTA DOME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus DELTA DOME.
CORTENEMA vs DELTA-DOME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Delta-dome agents, likely referring to delta-9-tetrahydrocannabinol (THC) analogs or synthetic cannabinoids, act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 receptors are primarily located in the central nervous system, modulating neurotransmitter release, while CB2 receptors are mainly in immune cells, influencing cytokine release and immune response.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Intramuscular or subcutaneous injection of 0.5 to 1 mL (5-10 mg/mL) every 4 to 6 hours as needed.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life is 2-4 hours in adults, prolonged to 4-8 hours in hepatic impairment; correlates with duration of pulmonary effects.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Primarily hepatic metabolism with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces as bile salts). Less than 1% excreted unchanged.
Category C
Category C
Corticosteroid
Corticosteroid